GIA
AXSM icon

Goodwin Investment Advisory’s Axsome Therapeutics AXSM Stock Holding History

Goodwin Investment Advisory’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Hold
4,241
– – 2.09% 12
2026
Q1 		$717K Hold
4,241
– – 0.85% 14
2025
Q4 		$775K Hold
4,241
– – 0.85% 14
2025
Q3 		$515K Hold
4,241
– – 0.55% 15
2025
Q2 		$443K Hold
4,241
– – 0.51% 16
2025
Q1 		$495K Hold
4,241
– – 0.77% 15
2024
Q4 		$359K Hold
4,241
– – 0.19% 30
2024
Q3 		$381K Hold
4,241
– – 0.17% 25
2024
Q2 		$341K Hold
4,241
– – 0.16% 26
2024
Q1 		$338K Buy
+4,241
New +$356K 0.16% 26

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goodwin Investment Advisory's AXSM Position: Q2 2026 in Review

Goodwin Investment Advisory held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 4,241 shares worth $1.04M. The position accounts for 2.09% of the portfolio, ranked #12.

Goodwin Investment Advisory first reported a position in AXSM in Q1 2024 and has held it in 10 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Goodwin Investment Advisory held 4,241 shares of Axsome Therapeutics worth $1.04M as of Q2 2026.
  • Goodwin Investment Advisory left its Axsome Therapeutics share count unchanged in Q2 2026.
  • Axsome Therapeutics made up 2.09% of Goodwin Investment Advisory's portfolio in Q2 2026, its #12 holding.
  • Goodwin Investment Advisory first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Goodwin Investment Advisory's 13F filing for Q2 2026, filed 19 Aug 2026.